News articles about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.3330630749611 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
NASDAQ:ALDX traded down $0.05 during trading hours on Friday, hitting $7.00. The company had a trading volume of 62,338 shares, compared to its average volume of 100,810. The stock has a market cap of $141.59, a P/E ratio of -5.00 and a beta of 0.56. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $11.90. The company has a quick ratio of 20.35, a current ratio of 20.35 and a debt-to-equity ratio of 0.02.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, March 29th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.04). analysts expect that Aldeyra Therapeutics will post -1.5 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Aldeyra Therapeutics (ALDX) Given Daily Media Sentiment Rating of 0.18” was first published by BBNS and is owned by of BBNS. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-aldeyra-therapeutics-aldx-stock-price/2037390.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.